Therapy

Antivirale Kombi-Therapie gegen RNA viren (z. B. Sars-CoV-2)

Kombi-Therapie für RNA-Virus-Erkrankungen mit Pyrimidin-Synthesehemmern und Nukleotidanaloga

Die COVID-19-Pandemie hat sich als die schwerste Gesundheitskrise der Neuzeit erwiesen. Zur Bekämpfung von RNA-Virusinfektionen wie SARS, Influenza, Hepatitis C, HIV und sogar Ebola wurde ein neuer kombinierter therapeutischer Ansatz aus Pyrimidin-Analoga und Pyrimidin-Biosynthese-Hemmern entwickelt.

read more

Antiviral combination therapy for RNA viruses (e. g. Sars)

Combination therapy for RNA virus diseases with pyrimidine synthesis inhibitors and nucleotide analogues

The COVID-19 pandemic has emerged as the most serious health crisis in modern times. To combat RNA viral infections like SARS, Influenza, Hepatitis C, HIV or even Ebola a new combination therapeutic approach of pyrimidine analogues and pyrimidine biosynthesis inhibitors has been discovered.

read more

Pan-Coronavirus Therapy - viral genome disruption with Cas13

Pan-Coronavirus Therapy

Pan-Coronavirus Therapy using a Cas13-guideRNA system. The antiviral effect is based on an Cas13-guideRNA-AAV vector with up to five guideRNAs, which target and disrupt the genome of the Coronavirus - blocking viral replication. A therapeutic effect was proven in vivo in the SARS-CoV2 Hamster Model.

read more

New therapeutic target against bacterial or viral infections

New therapeutic target against bacterial or viral infections

Targeting key proteins in viral or bacterial pathogens is an appealing way to combat infectious diseases. A new protein domain has been discovered as a therapeutic target.

read more

Reducing mortality after Aortic-Valve Implantation

Reducing the mortality rate of patients after Aortic-Valve Implantation by Anti-Fibrotic Treatment

A subpopulation of patients with a very high rist to die in only one year after an aortic valve implantation (AVI) was identified. A novel treatment may save lives by analysing the level of fibrosis in the heart tissue.

read more

GMP-compatible methods for tissue-engineered human heart tissue

GMP-compatible Methods for producing tissue-engineered human heart muscle from stem cells

Heart tissue engineering using stem cells is a recently developed technique to construct a three dimensional cell structure from cardiomyocytes or directly from progenitor cells. Scientists at the University of Göttingen developed two new and fully defined methods for serum-free production of engineered human heart muscles.

read more

Treatment of cardiac arrhythmia via re-expression of TBX5

Treatment of cardiac arrhythmia via re-expression of TBX5 (gene therapy)

Cardiovascular disease is the number one cause of death worldwide. Scientists at the University Medical Center Göttingen developed a gene therapy (TBX5 re-expression) for use in the prevention and acute treatment of a heart disease and associated complications (e.g. cardiac arrhythmia and sudden cardiac death).

read more

Pharmacologically controlled vector for CNS gene therapies

Pharmacologically controlled vector for CNS gene therapies

Gene therapies are irreversible and not controlable in case of side effects. We offer a pharmacologically controlled one-vector expression system of a therapeutic factor (i.e. GDNF) with zero background expression, based on mifepristone (Mfp)-Gene Switch system, for the therapy of neurological diseases.

read more

Bio-engineered neuronal organoids from human stem cells

Bio-engineered neuronal organoids from human stem cells

Scientists at the University Medical Center Göttingen, Germany developed a reproducible, robust and fully defined method for serum-free production of human bio-engineered neuronal organoids (BENOs) from stem cells. This new method will allow for reproducible production of oganoids with fully functional neuronal network activity.

read more

Improved marker vaccine against classical swine fever

Improved marker vaccine against classical swine fever

Scientists at the University of Veterinary Medicine Hanover developed a new marker vaccine for classical swine fever based on chimeric pestiviruses with improved DIVA (Differentiating Infected from Vaccinated Animals) properties. The used marker Erns is a chimeric sequence of two different and remotely related pestiviruses.

read more

EYA1— Biomarker and Target for kidney fibrosis

EYA1 — Biomarker and therapeutic target for kidney fibrosis

The EYA1 splicing was found to be linked with the progression of fibrosis. Patients expressing predominantly EYA1-A ("bad" variant) end up in the end stage renal disease earlier and suffer from a higher mortality. A shift of splicing towards EYA1-C ("good" variant) effectively attenuates fibrosis in vivo (mouse model).

read more

1-vector otoferlin DFNB9 gene therapy

1-vector otoferlin DFNB9 gene therapy

Due to the large OTOF size a one-vector delivery has remained challenging.Our technology: Gene-therapy of the otoferlin gene (OTOF) with overloaded AAV virus mediated delivery into the cochlea. In vivo proof-of-concept successfully achieved.

read more

Targeted Demethylating Gene Therapy of Fibrosis

Targeted Demethylating Gene Therapy of Fibrosis

All-in-one construct dCas9-TET3CD-(target gene)-sgRNA for targeted fibrosis therapy through demethylation of the genes RASAL1, LRFN2, KLOTHO (i.e. in heart, kidney, liver, lung, cancer). Normal re-expression of these genes has been achieved successfully in vitro and in vivo as well as a reduction of fibrosis.

read more

Prodrugs/drugs for a selective ADC tumor therapy

Prodrugs/drugs for a selective ADC tumor therapy

Scientists at the University of Göttingen developed new highly potent drugs (with an IC50 in the pico-molar range) as well as a selective tumor therapy through their prodrugs. Selectivity is achieved by antibody tumor targeting. The highly soluble prodrugs are activated into the cytotoxic drugs only at tumor site.

read more

Search

A subsidiary of

Georg-August-Universität Göttingen